Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis-Reference-Cited by-同舟云学术

Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis

Published:2020-06-22 Issue:16 Volume:126 Page:3758-3767
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Grover Shilpa¹²,Dougan Michael¹³,Tyan Kevin¹⁴^ORCID,Giobbie‐Hurder Anita⁵,Blum Steven M.¹⁴⁶⁷,Ishizuka Jeffrey⁸^ORCID,Qazi Taha²⁹,Elias Rawad¹⁰,Vora Kruti B.¹,Ruan Alex B.¹,Martin‐Doyle William¹¹¹,Manos Michael⁴,Eastman Lauren⁴,Davis Meredith⁴,Gargano Maria⁴,Haq Rizwan¹⁴,Buchbinder Elizabeth I.¹⁴¹¹,Sullivan Ryan J.⁷,Ott Patrick A.¹⁴⁶¹¹,Hodi F. Stephen¹⁴,Rahma Osama E.¹⁴

Affiliation:

1. Harvard Medical School Boston Massachusetts

2. Division of Gastroenterology, Department of Medicine Brigham and Women's Hospital Boston Massachusetts

3. Division of Gastroenterology, Department of Medicine Massachusetts General Hospital Boston Massachusetts

4. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts

5. Division of Biostatistics Department of Data Sciences Dana‐Farber Cancer Institute Boston Massachusetts

6. Broad Institute at MIT and Harvard Cambridge Massachusetts

7. Massachusetts General Hospital Cancer Center Boston Massachusetts

8. Departments of Medicine and Pathology Yale University School of Medicine New Haven Connecticut

9. Digestive Disease & Surgery Institute Cleveland Clinic Cleveland Ohio

10. Hartford HealthCare Cancer Institute Hartford Connecticut

11. Department of Medicine Brigham and Women's Hospital Boston Massachusetts

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

Massachusetts General Hospital

American Gastroenterological Association

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32966

Reference68 articles.

1. Cancer Immunotherapy

2. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

3. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

4. CTLA-4 and PD-1 Pathways

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU;Revista Española de Enfermedades Digestivas;2024

2. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU;Gastroenterología y Hepatología;2024-01

3. Clinical Management of Gastrointestinal and Liver Toxicities of Immune Checkpoint Inhibitors;Clinical Colorectal Cancer;2023-12

4. Stocking the toolbox—Using preclinical models to understand the development and treatment of immune checkpoint inhibitor‐induced immune‐related adverse events;Immunological Reviews;2023-08-10

5. Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis;Frontiers in Immunology;2023-08-09